Augmentation of atrial natriuretic peptide actions produces physiologic effects like vasodilatation and natriuresis, which may be pharmacologically useful in hypertension and congestive heart failure.
Atrial natriuretic peptide (ANP) is a 28 amino-acid polypeptide secreted into the blood by atrial myocytes after atrial pressure and distension. Although its role in humans is not clear, it can produce a variety of physiologic effects including vasodilatation, natriuresis, and suppression of the renin-angiotensin-aldosterone axis. These actions are potentially useful in a variety of pathologic states such as hypertension and congestive heart failure, and diverse methods to augment the effects of ANP in these states have been devised. The results are exciting and, despite some problems, may lead to the pharmacologic use of enhancement of ANP actions in several clinical disorders.
Deutsch et al. (Thu,) conducted a review in Hypertension and congestive heart failure. Atrial natriuretic peptide (ANP) enhancement was evaluated. Augmentation of atrial natriuretic peptide actions produces physiologic effects like vasodilatation and natriuresis, which may be pharmacologically useful in hypertension and congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: